Catheter Precision Announces Accepted Publication in Leading European Medical Journal

Rhea-AI Summary

Catheter Precision (NYSE American: VTAK) announced that a VIVO study has been accepted for publication in EP Europace on April 13, 2026. The 31‑patient study mapped 48 VTs and found ECGi mapping with VIVO accurately predicted arrhythmogenic substrate for scar‑dependent VT and may improve procedural efficiency.

The study reported VIVO localization in NICM patients showed 100% specificity and 66.7% sensitivity for epicardial VTs versus a four‑step ECG algorithm (sensitivity 50%, specificity 0%). The company plans a larger multi‑center study later in 2026.

AI-generated analysis. Not financial advice.

Positive

• Study accepted in EP Europace, a leading electrophysiology journal
• VIVO mapped 48 ventricular tachycardias across 31 patients
• NICM specificity 100% and sensitivity 66.7% for epicardial VT localization
• Company plans a larger multi‑center study later in 2026

Negative

• Small sample size: only 31 patients, limiting statistical power
• Sensitivity below 70% (66.7%) may miss some epicardial VT localizations

News Market Reaction – VTAK

+2.52%

3 alerts

+2.52% News Effect

+12.0% Peak Tracked

+$84K Valuation Impact

$3.42M Market Cap

0.4x Rel. Volume

On the day this news was published, VTAK gained 2.52%, reflecting a moderate positive market reaction. Argus tracked a peak move of +12.0% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $84K to the company's valuation, bringing the market cap to $3.42M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patient count: 31 patients VTs mapped: 48 VTs VIVO specificity: 100% +3 more

6 metrics

Patient count 31 patients VIVO scar-dependent VT study

VTs mapped 48 VTs Mapped with VIVO and standard systems

VIVO specificity 100% Epicardial VT localization in NICM patients

VIVO sensitivity 66.7% Epicardial VT localization in NICM patients

Algorithm sensitivity 50% Traditional four-step ECG-based algorithm

Algorithm specificity 0% Traditional four-step ECG-based algorithm

Market Reality Check

Price: $0.8897 Vol: Volume 284,917 is 1.28x t...

normal vol

$0.8897 Last Close

Volume Volume 284,917 is 1.28x the 20-day average of 223,031, indicating elevated interest before this news. normal

Technical Shares at $1.19 are trading below the 200-day MA of $2.43 and sit 92.41% under the 52-week high.

Peers on Argus

VTAK was down 1.65% while peers were mixed: BBLG appeared in momentum scanners m...

1 Up 1 Down

VTAK was down 1.65% while peers were mixed: BBLG appeared in momentum scanners moving down 3.97% and TIVC moved up 9.58%. With no clear directional clustering and no peer news, the setup looks stock-specific rather than a sector-wide move.

Historical Context

5 past events · Latest: Mar 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 25	Aviation platform update	Positive	-4.2%	Expanded Flyte Hops Vision Jet regional platform and fleet growth plans.
Mar 31	Earnings and strategy	Positive	-3.8%	Reported 2025 results with strong revenue growth and outlined strategic expansion.
Apr 02	Asset sale process	Positive	-1.1%	Hired advisor to market cardiac electrophysiology assets and focus on Flyte.
Apr 06	LockeT clinical data	Positive	+2.1%	Peer‑reviewed LockeT study in 139 patients showing strong safety and efficacy profile.
Apr 08	Conference attendance	Positive	-1.7%	Planned presence at EHRA conference to showcase data and support LockeT adoption.

Pattern Detected

Across recent announcements—conference plans, clinical data, strategic shifts, and results—VTAK often traded down following ostensibly positive news, with only one clear positive reaction to favorable LockeT data.

Recent Company History

Over the last few weeks, VTAK has reported multiple developments, including Flyte Hops expansion on Mar 25, 2025 results and strategic expansion on Mar 31, engaging a strategic advisor to market its cardiac electrophysiology business on Apr 2, LockeT clinical data acceptance on Apr 6, and EHRA conference attendance plans on Apr 8. Despite generally constructive news, four of these five events were followed by negative price reactions, showing a tendency for softness around updates.

Market Pulse Summary

This announcement highlights peer‑reviewed clinical evidence supporting VIVO’s accuracy in scar‑depe...

Analysis

This announcement highlights peer‑reviewed clinical evidence supporting VIVO’s accuracy in scar‑dependent ventricular tachycardia, including 100% specificity and 66.7% sensitivity versus weaker performance from a traditional ECG algorithm. It adds to recent clinical and strategic updates across VTAK’s portfolio. Investors may watch for the planned larger multi‑center study, ongoing efforts to monetize cardiac assets, and how these data points influence adoption and potential transaction value for the VIVO platform.

Key Terms

ventricular tachycardia, electrocardiographic imaging, electrophysiology, electroanatomical mapping, +3 more

7 terms

ventricular tachycardia medical

"highlights the feasibility of VIVO for scar-related ventricular tachycardia (VT)"

A fast, abnormal heartbeat that starts in the heart’s lower chambers and can sharply reduce blood flow, potentially causing dizziness, fainting or, in severe cases, sudden collapse; picture an engine running so fast it loses power. For investors, ventricular tachycardia matters because demand for drugs, devices, diagnostic tests and emergency care tied to this condition affects clinical trial results, regulatory approvals, revenue prospects and legal or safety risks for healthcare companies.

electrocardiographic imaging medical

"Accuracy of a non-invasive electrocardiographic imaging system in scar-dependent"

A noninvasive medical technique that maps the heart’s electrical activity by combining signals from sensors placed on the body with imaging data to create a detailed picture of where and how electrical impulses travel across the heart. Think of it as using an external radar to locate electrical “hot spots” inside the chest; investors care because it can make diagnosis and treatment of heart rhythm problems faster, safer and more precise, creating demand for related devices, software and clinical services.

electrophysiology medical

"leading European electrophysiology journal"

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

electroanatomical mapping medical

"mapped 48 VTs with VIVO and standard of care electroanatomical mapping systems"

A medical technique that builds a detailed 3D picture of the heart’s shape and its electrical activity, used during procedures to find and treat abnormal heart rhythms. Think of it as a GPS for the heart that helps doctors target therapy more precisely, which matters to investors because better mapping can improve procedure success, shorten operating time, raise adoption of specialized equipment, and influence revenue, regulation and reimbursement trends in cardiac device and services markets.

epicardial medical

"compares VIVO’s predictability of epicardial VTs to a four step ECG based algorithm"

Epicardial describes the outer surface or layer of the heart and anything that involves working on or near that outer layer. It matters to investors because treatments, devices, or procedures that target the epicardial area can have different technical challenges, safety profiles and regulatory requirements than those done inside the heart chambers—think of fixing wiring on the outside of a machine versus working inside it—which affects development costs, approval risks and market potential.

non-ischemic cardiomyopathy medical

"In patients with Non-ischemic cardiomyopathy (NICM), the VIVO localization had"

Non-ischemic cardiomyopathy is a condition where the heart muscle becomes weak or changes shape for reasons other than reduced blood flow from blocked coronary arteries. Think of the heart as a pump whose walls are stretched or stiffened by infection, genetics, toxins, or other causes rather than a clogged pipe; that weakened pump raises risks of heart failure, hospital stays and long-term treatment. Investors track it because its prevalence and severity drive demand for drugs, devices, diagnostic tests and care services, and can influence clinical trial and regulatory activity in the cardiovascular sector.

specificity medical

"the VIVO localization had a 100% specificity and 66.7% sensitivity"

Specificity measures how well a diagnostic test or screening correctly identifies people who do not have a condition — the percentage of healthy cases the test labels as negative. Think of it as a smoke alarm that stays quiet when there’s no fire; high specificity means fewer false alarms. For investors, specificity affects regulatory approval, clinical adoption, follow-up costs, and the perceived reliability and market potential of medical products.

AI-generated analysis. Not financial advice.

Clinical Evidence Further Demonstrates Efficacy and Accuracy of VIVO for Ventricular Procedures

FORT MILL, S.C., April 13, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”) today announced that the results of a recently concluded VIVO study have been accepted in EP Europace, the leading European electrophysiology journal.

The EP Europace journal provides an avenue of communication for top-quality European and international original, scientific work and reviews in the fields of arrhythmias, pacing and cellular electrophysiology. The journal offers readers a collection of contemporary, original, peer-reviewed papers, invited papers and editorial comments, together with book reviews and correspondence.

The accepted manuscript titled “Accuracy of a non-invasive electrocardiographic imaging system in scar-dependent ventricular tachycardia: Relationship to arrhythmogenic substrate and imaging defined scar” highlights the feasibility of VIVO for scar-related ventricular tachycardia (VT) was led by Professor Tarv Dhanjal, MBChB(hons) PhD FRCP FESC FEHRA, Professor of Cardiology (University of Warwick). This study included 31 patients and mapped 48 VTs with VIVO and standard of care electroanatomical mapping systems to determine accuracy. The study concluded that ECGi mapping with VIVO can accurately predict the arrhythmogenic substrate for scar-dependent VT and incorporation of ECGi mapping to conventional VT ablation workflows may improve procedural efficiency.

Of additional importance, this study compares VIVO’s predictability of epicardial VTs to a four step ECG based algorithm. In patients with Non-ischemic cardiomyopathy (NICM), the VIVO localization had a 100% specificity and 66.7% sensitivity, while a traditional four-step ECG-based algorithm had a sensitivity and specificity of 50% and 0%, further demonstrating VIVO’s capabilities to improve procedural workflow.David Jenkins, CEO of Catheter Precision, says, “This study demonstrates that VIVO works in a wide range of patients, including those with scar related ventricular tachycardia and that it can improve procedural workflow and reduce procedure time even in very difficult procedures like epicardial VT. We are very pleased with the outcomes of this study and plan to start a larger, multi-center study later this year to prove out these results on a larger scale.”  

About VIVO™  
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “potential,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, expectations regarding potential strategic transactions, valuation outcomes, market opportunities, and the Company’s growth strategy. These statements involve risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Company’s filings with the SEC, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

#   #   #

FAQ

What did Catheter Precision (VTAK) announce on April 13, 2026 about the VIVO study?

They announced acceptance of a VIVO study for publication in EP Europace, demonstrating feasibility and accuracy in scar‑dependent VT mapping. According to the company, the study included 31 patients and mapped 48 VTs showing potential workflow benefits.

How accurate was VIVO in localizing epicardial VTs in NICM patients in the VTAK study?

VIVO localization showed 100% specificity and 66.7% sensitivity for epicardial VTs in NICM patients. According to the company, this outperformed a four‑step ECG algorithm that had 50% sensitivity and 0% specificity.

How many patients and VTs were included in the Catheter Precision VIVO study (VTAK)?

The study enrolled 31 patients and mapped 48 ventricular tachycardias using VIVO and standard mapping systems. According to the company, comparisons assessed VIVO accuracy versus conventional electroanatomical mapping workflows.

What potential clinical benefit did Catheter Precision claim for VIVO in VT ablation procedures?

VIVO may improve procedural efficiency and reduce procedure time when incorporated into conventional VT ablation workflows. According to the company, the study concluded ECGi mapping with VIVO can accurately predict arrhythmogenic substrate for scar‑dependent VT.

Will Catheter Precision (VTAK) follow up the published VIVO study with further research?

Yes. The company plans to start a larger, multi‑center study later in 2026 to validate these results on a broader scale. According to the company, this aims to prove findings in a larger patient population.